Board

Patrik DahlenPatrik Dahlen

Patrik Dahlen joined the board of ViroGates in April 2022. He has been the Chairman of the Board since May.

Education: Ph.D., Biochemistry – University of Turku 1991; MSc, Biochemistry – Åbo Akademi University 1985

Competencies: Seasoned executive with more than 35 years of experience in the international life science, med-tech, and diagnostics business. Leadership experience in development, manufacturing, and commercial companies with solutions for laboratories and hospitals. Leadership experience within companies ranging from 10-2000 people. Experience from companies owned by family offices, Venture capital, Private Equity, and publicly traded companies. Board memberships from more than 10 companies including Leo Pharma, SSI Diagnostica, AdvaLight, Proxeon etc.

Directorships: • SSI Diagnostica A/S (Board member) • Visiopharm A/S (Chairman of the Board) • Advalight ApS (Chairman of the Board) • Immudex ApS (Board member)

Shareholdings: Shares: 0, Warrants (vested): 0 (30 September 2020)

Patrik is independent of the issuer, major shareholders and senior management.

Valérie Soulier

Valérie Soulier Patrik Dahlen joined the board of ViroGates in April 2022.
Founder & Managing Director 2C4P

Education: Ph.D., Human Biology-Neurochemistry – University Claude Bernard, Lyon, and Karolinska; Institute Stockholm 1995; Diploma of Advanced Studies – University Claude Bernard, Lyon 1992; MSc, Biochemistry – University Claude Bernard, Lyon 1991

Competencies: Proven Leadership ability, multicultural management, and general corporate experience from helping healthcare companies for more than 25 years. Experience from diagnostics companies such as Radiometer/Danaher, Siemens Healthineers, Dade Behring, Abbott Labs. Hands-on experience in global marketing departments, and innovative product launches, including leadership of 100 persons in an international environment.

Directorships: • Founder & Managing Director 2C4P (Business / Leadership Consultant & Executive Coach) • BioAnalyt GmbH (Board member) • European Innovation Council (EIC) Accelerator Business Coach

Shareholdings: Shares: 0, Warrants (vested): 0 (28 April 2022)

Valérie is independent of the issuer, major shareholders and senior management.

Lars Krogsgaard

Lars Krogsgaard joined the board of ViroGates in April 2016.
Professional board member and investor

Education: B.Sc. in Economics, Copenhagen Business School; MBA in Finance and International Business, Stern School of Business, New York.

Competencies: Track-record as active investor, owner and board member in more than 25 Nordic companies incl. other growth companies; strategic development; business development; risk management; financing, M&A.

Directorships: • Daintel ApS (BM) • DCR Solutions A/S (BM) • Forward Capital A/S (BM, M)
• 4AM ApS (M) • Samplix A/S (MB) • 6AM ApS (M)

Shareholdings: Shares: 325,965, Warrants (vested): 0 (30 September 2020)

Lars is not an independent director.

Lars Kongsbak

Lars Kongsbak joined ViroGates in February 2015.
President and CEO of Samplix ApS

Education: M.Sc. in Biology, Copenhagen University; Ph.D. in molecular biology from the Technical University of Denmark (DTU)

Competencies: Former President & CEO of listed biopharmaceutical company; strategic business development; M&A; financing, broad-based leadership experience; senior scientist positions at blue-chip companies.

Directorships: • BlueBee Holding BV (BM)

Shareholdings: Shares: 6,968, Warrants (vested): 37,070 (30 September 2020)

Lars is independent of the issuer, major shareholders and senior management.

+800

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates